IJIMM, Volume 2, Issue 12, 2024 ISSN: 2995-5319
http://medicaljournals.eu/index.php/IJIMM/issue/view/3
INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

Understanding Emphysematous Pyelonephritis: Causes, Diagnosis, and Management

Shodiev Ulmas Mustafoevich
Assistant of the Department of Urology, Nephrology and Hemodialysis of the Bukhara State Medical Institute

Annotation: Emphysematous pyelonephritis (EPN) is a rare, severe, life-threatening necrotizing infection of the kidney characterized by the presence of gas within the renal parenchyma, collecting system, or perinephric tissues. It primarily affects individuals with compromised immune systems, particularly those with uncontrolled diabetes mellitus. Early recognition and prompt management are crucial to prevent significant morbidity and mortality.

EPN is caused by gas-forming bacterial or fungal pathogens. The condition arises when certain bacteria, such as *Escherichia coli*, *Klebsiella pneumoniae*, or rarely *Proteus*, *Pseudomonas*, or *Candida* species, ferment glucose, producing gas as a byproduct. The gas accumulates in the renal parenchyma and surrounding structures, exacerbating tissue destruction and inflammation.

Key contributing factors include:

1. **Hyperglycemia**: Promotes bacterial growth and fermentation.
2. **Obstruction or ischemia**: Impairs immune response and clearance of infection.
3. **Immunosuppression**: Limits the body's ability to fight infections.

Epidemiology of the disease are followed as

- **Prevalence**: Although rare, EPN is more commonly reported in diabetic patients, with studies showing diabetes in 80-90% of cases.
- **Gender and Age**: Women are affected more often than men due to their predisposition to urinary tract infections (UTIs). Most cases occur in middle-aged to older adults.
- **Risk Factors**:

- Poorly controlled diabetes mellitus.
- Urinary tract obstruction (e.g., nephrolithiasis, strictures).
- Chronic kidney disease.
- Immunosuppression (e.g., transplant recipients, cancer patients).

Clinical Presentation. Symptoms of EPN often overlap with other forms of severe pyelonephritis but are typically more severe. Common presentations include:

- **Systemic Symptoms**:

- Fever.
- Chills.
- Malaise.
- Septic shock in advanced cases.

- **Localized Symptoms**:

- Flank pain.

- Abdominal tenderness.
- Dysuria or hematuria.

➢ **Signs of Gas Accumulation**:

- Crepitus on palpation over the affected kidney, although rare.

Diagnosis. Imaging

Imaging is critical for diagnosing EPN. The hallmark finding is the presence of gas in or around the kidney.

1. **Plain Radiography**: May show gas overlying the renal silhouette but is less sensitive.
2. **Ultrasound**: Useful in detecting hyperechoic foci with posterior acoustic shadowing but has limitations in identifying detailed anatomical involvement.
3. **Computed Tomography (CT)**: The gold standard for diagnosing EPN. CT can:

➢ Identify gas in the renal parenchyma, collecting system, or perinephric tissues.

➢ Determine the extent of infection.

➢ Guide management decisions.

CT Classification (Huang and Tseng, 2000):

➢ Class 1: Gas in the collecting system only.

➢ Class 2: Gas in the renal parenchyma without extension to the extrarenal space.

➢ Class 3A: Gas extending into the perinephric space.

➢ Class 3B: Gas extending into the pararenal space.

➢ Class 4: Bilateral EPN or involvement of a solitary kidney.

Laboratory Findings

➢ Leukocytosis with neutrophilia.

➢ Elevated inflammatory markers (e.g., CRP, ESR).

➢ Hyperglycemia and glycosuria in diabetic patients.

➢ Positive urine and/or blood cultures identifying the causative organism.

Medical Treatment. 1. Antibiotics:

➢ Empiric therapy covering Gram-negative bacteria, such as third- or fourth-generation cephalosporins, carbapenems, or aminoglycosides.

➢ Adjusted based on culture sensitivity results.

1. **Glycemic Control**:

➢ Strict blood glucose regulation in diabetic patients to mitigate bacterial growth.

2. **Supportive Care**:

➢ Intravenous fluids to maintain hydration.

➢ Management of septic shock with vasopressors, if needed.

3. Interventional and Surgical Treatment 1. Percutaneous Drainage:

➢ Often the first-line intervention for localized abscesses or gas.

➢ Reduces the need for nephrectomy in select patients.

4. **Nephrectomy**:

- Indicated for extensive disease (e.g., Class 3B or 4) or failure of conservative management.
- Can be life-saving in cases of fulminant infection.

5. **Ureteral Stenting or Nephrostomy**:

- Useful in cases of obstruction to relieve pressure and facilitate drainage.

The prognosis of EPN depends on several factors:

- **Favorable Outcomes**:

- Early diagnosis and appropriate management.
- Localized disease (Class 1 or 2).

- **Poor Prognostic Factors**:

- Bilateral involvement or solitary kidney disease.
- Delayed intervention.
- Presence of septic shock or multi-organ failure.
- Underlying comorbidities like advanced diabetes or chronic kidney disease.

Reported mortality rates range from 20-40%, emphasizing the importance of timely treatment.

Prevention. 1. Glycemic Control: Maintaining optimal blood glucose levels in diabetic patients.

1. **UTI Management**: Prompt treatment of urinary infections to prevent progression.
2. **Regular Monitoring**: Screening for kidney function and imaging in high-risk patients.

Conclusion. Emphysematous pyelonephritis is a life-threatening condition that requires a high index of suspicion for early diagnosis and prompt management. Advances in imaging techniques and interventional approaches have improved outcomes significantly. However, optimal glycemic control and prevention of UTIs remain essential in reducing the incidence of this serious infection. Clinicians must remain vigilant in high-risk populations to ensure timely intervention and improved prognosis.

Literature Review

1. Pontin AR, Barnes R.D. Current management of emphysematous pyelonephritis. Nat Rev Urol 2009;6(5):272-279.
2. Ubee SS, McGlynn L. Emphysematous pyelonephritis. Br J Urol Intern 2010;107(9):1474–8.
3. Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 2000;160(6):797-805.
4. Bamanikar A, Dhobale S. Fever with abdominal pain and diabetes – Is it Emphysematous Pyelonephritis? Malays J Med Sci 2014;21(3):85-88.
5. Kelly HA, MacCullem WG. Pneumaturia. JAMA 1898;31(8):375-381.
6. Schultz EHJr, Klorfein EH. Emphysematous pyelonephritis. J Urol 1962;87:762–766. https://doi.org/10.1016/S0090-4295(96)00501-8
7. Sugandh S, Edward DK. Emphysematous Pyelonephritis [Internet]. New York (NY): WebMD. 2013 [cited 2013 Apr 11]. Available from
8. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26(3-4):259-265.
9. Cheng YT, Wang HP, Hsieh HH. Emphysematous pyelonephritis in a renal allograft: successful treatment with percutaneous drainage and nephrostomy. Clin Transplant 2001;15(5):364-367

10. Aikawa N, Fujishima S, Endo S. Multicenter prospective study of procalcitonin as an indicator of sepsis. J Infect Chemother 2005;11(3):152-159.

11. Wan YL, Lee TY, Bullyard MJ. Acute gas-producing bacterial renal infection: correlation between imaging findings and clinical outcome. Radiology 1996;198:433-438

12. Michaeli J, Mogle P, Perlberg S, Heiman S, Caine M. Emphysematous pyelonephritis. J Urol 1984;131(2):203-208